Literature DB >> 29952822

Endophthalmitis Following XEN Stent Exposure.

Bhavani Karri1, Chandni Gupta, Divya Mathews.   

Abstract

BACKROUND: XEN45 Gel stents are in their infancy, and clinical expertise with microsurgical glaucoma devices are increasing. The soft flexible nature of the XEN stent together with its malleability under the conjunctival tissue should negate any risk of exposure of the XEN45 stent (XEN). However, we report a case in which sight-threatening endophthalmitis was the presenting feature of this complication. CASE REPORT: We present a case of uncomplicated XEN implantation that developed endophthalmitis 4 months after surgery. She gave an 8-day history of diarrhea before presentation. She was noted to have exposure of the XEN stent at the point of entry of the XEN into the subconjunctival space. The stent was removed, pars plana vitrectomy was carried out, and intravitreal antibiotics were administered. Achieving low intraocular pressures, bearing in mind her preservative allergy, became a challenge, as we struggled to manage her advanced glaucoma medically. A CyPass Micro-Stent was subsequently inserted to control the intraocular pressure.
CONCLUSIONS: Episodes of XEN stent exposure may not be so isolated. We postulate that poor handwashing transmitted the causative organism to the exposed stent, which then resulted in endopthalmitis. We would like to highlight a few learning points from this case.

Entities:  

Mesh:

Year:  2018        PMID: 29952822     DOI: 10.1097/IJG.0000000000001012

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  7 in total

1.  Postoperative complications of Ab-Interno XEN implantation in primary angle closure glaucoma.

Authors:  Samuel Asanad; Sachin Kalarn; Mona A Kaleem
Journal:  Am J Clin Exp Immunol       Date:  2021-02-15

2.  Is the Xen® Gel Stent really minimally invasive?

Authors:  Juliette Buffault; Christophe Baudouin; Antoine Labbé
Journal:  Am J Ophthalmol Case Rep       Date:  2020-08-04

3.  Efficacy and safety at 6 months of the XEN implant for the management of open angle glaucoma.

Authors:  Juliette Buffault; Martin Graber; Djawed Bensmail; Élisa Bluwol; Marie-Nathalie Jeanteur; Olivia Abitbol; Nassima Benhatchi; Lauren Sauvan; Yves Lachkar
Journal:  Sci Rep       Date:  2020-03-11       Impact factor: 4.379

4.  Late-onset Endophthalmitis after XEN45® Implantation: A Retrospective Case Series and Literature Review.

Authors:  Raquel Burggraaf-Sánchez de Las Matas; Laura Such-Irusta; Enrique A Alfonso-Muñoz; Héctor Mascarós-Mena; Aitor Lanzagorta-Aresti; Jorge Mataix-Boronat; Carolina Font-Julià
Journal:  J Curr Glaucoma Pract       Date:  2021 Sep-Dec

5.  "Culture-positive exogenous endophthalmitis related to XEN45 gel stent implantation".

Authors:  Aaron W Ng; Vivien C Yip; Bryan C Ang; Leonard W Yip; Boon Ang Lim
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-29

6.  PreserFlo MicroShunt® exposure: a case series.

Authors:  Roxane Bunod; Mathieu Robin; Juliette Buffault; Chafik Keilani; Antoine Labbé; Christophe Baudouin
Journal:  BMC Ophthalmol       Date:  2021-07-10       Impact factor: 2.209

7.  [Endophthalmitis after perforation of the conjunctiva by a glaucoma gel-stent implant].

Authors:  Laila El Moussaoui; Yassin Djalali-Talab; Peter Walter; Niklas Plange; David Kuerten; Matthias Fuest
Journal:  Ophthalmologe       Date:  2020-12       Impact factor: 1.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.